Abstract
Paraproteinaemia following allo-SCT is common. We analysed 91 consecutive patients undergoing allo-SCT; conditioning included alemtuzumab in 42% of the patients. Paraproteinaemia incidence at 2 years was 32%. In univariate analysis paraproteinaemia was associated with unrelated donor, age, recipient seropositivity for CMV and alemtuzumab conditioning (hazard ratio (HR) 3.93, P=0.0006). Paraproteinaemia was not associated with haematological diagnosis; disease status at transplant; varicella zoster, herpes simplex or EBV serology; reduced-intensity vs myeloablative conditioning or GVHD. CMV reactivation-more frequent in alemtuzumab recipients-was associated with paraproteinaemia (HR 7.52, P
Original language | English |
---|---|
Pages (from-to) | 993-9 |
Number of pages | 7 |
Journal | Bone Marrow Transplantation |
Volume | 46 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2011 |
Keywords
- Antibodies, Neoplasm
- Transplantation Conditioning
- Humans
- Retrospective Studies
- Paraproteinemias
- Virus Activation
- Cytomegalovirus
- Adult
- Hematopoietic Stem Cell Transplantation
- Middle Aged
- Antibodies, Monoclonal, Humanized
- Female
- Male
- Survival Analysis